Market Size of Hyperkalemia Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 16.79 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Hyperkalemia Treatment Market Analysis
The hyperkalemia treatment market is poised to register a CAGR of 16.79% over the forecast period.
The COVID-19 pandemic impacted the market significantly during the pandemic phase. Since the beginning of the pandemic, there have been numerous discussions regarding the impact of COVID-19 on several areas of human health, and hyperkalemia is no exception. Several scientists conducted observational studies to find the correlation between hyperkalemia and COVID-19. For instance, according to an article published by PubMed in August 2021, there have been numerous reports of electrolyte issues, notably potassium imbalances, as frequent clinical symptoms of COVID-19. In this research, scientists have explored how SARS-CoV-2 may alter potassium homeostasis by reducing epithelial sodium channels' activity (ENaC) and explained the prevalence of hypokalemia. and concluded that there is a correlation between COVID-19 and hyperkalemia. Thus, the use of drugs to treat hyperkalemia increased during the pandemic. However, as the pandemic has subsided currently, the market is expected to have stable growth during the forecast period of the study.
Factors such as the increasing prevalence of hyperkalemia, the rising focus on research and development, and an increasing number of strategic alliances among major market players are anticipated to drive the market's growth. For instance, the article published by Healthline in March 2022 stated that high potassium levels, or hyperkalemia (HK), affect 40% to 50% of people with chronic kidney disease (CKD) globally, and nearly 40% of people with congestive heart failure (CHF) develop high potassium levels.
In addition, another article published by PubMed Central in October 2021 stated that when the research was conducted to characterize the progression of HK and identify the risk factors for HK progression, greater rates of HK progression were observed in individuals with advanced CKD stages, while higher potassium levels were also found among heart failure, hypertension, and diabetes patients. Such disease prevalence is expected to necessitate the availability of drugs and diagnostics to the target population, contributing to the market's growth.
Therefore, owing to the above-mentioned factors, such as the increasing prevalence of hyperkalemia and the rising focus on research and development, the market studied is expected to grow over the forecast period. However, the high cost of drugs is anticipated to hinder market growth over the forecast period.
Hyperkalemia Treatment Industry Segmentation
According to the scope of this report, hyperkalemia (HK), a condition characterized by elevated serum potassium, is caused by disturbances in potassium homeostasis within the body. The hyperkalemia treatment market is segmented by drug (Sodium Zirconium Cyclosilicate, Beta2-Agonist, Sodium Polystyrene Sulfonate, and Other Drugs), type of disease (Acute Hyperkalemia and Chronic Hyperkalemia), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug | |
| Sodium Zirconium Cyclosilicate | |
| Beta2 Agonist | |
| Sodium Polystyrene Sulfonate | |
| Other Drugs |
| By Type of Disease | |
| Acute Hyperkalemia | |
| Chronic Hyperkalemia |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Hyperkalemia Treatment Market Size Summary
The hyperkalemia treatment market is expected to experience significant growth over the forecast period, driven by factors such as the increasing prevalence of hyperkalemia, heightened research and development activities, and strategic alliances among key market players. The market's expansion is further supported by the rising incidence of chronic conditions like chronic kidney disease and heart failure, which are closely associated with hyperkalemia. The COVID-19 pandemic initially impacted the market, but it also led to increased awareness and demand for hyperkalemia treatments due to the observed electrolyte imbalances in COVID-19 patients. As the pandemic's effects wane, the market is anticipated to stabilize and continue its upward trajectory, although the high cost of treatments may pose challenges to growth.
Regionally, North America is projected to hold a significant share of the market, with the United States leading due to its substantial healthcare expenditure and the growing prevalence of hyperkalemia. The burden of chronic kidney disease and associated comorbidities in the region necessitates the development and availability of advanced treatment options. Canada also shows a high demand for hyperkalemia treatments, driven by the condition's impact on healthcare utilization. The market is characterized by a consolidated landscape, with major players like AstraZeneca, Ardelyx, CSL Limited, Sanofi SA, and Perrigo Company PLC dominating the scene. Recent regulatory updates and positive clinical trial outcomes for key treatments are expected to further propel market growth.
Hyperkalemia Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Hyperkalemia
-
1.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances
-
-
1.3 Market Restraints
-
1.3.1 High Cost of Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Drug
-
2.1.1 Sodium Zirconium Cyclosilicate
-
2.1.2 Beta2 Agonist
-
2.1.3 Sodium Polystyrene Sulfonate
-
2.1.4 Other Drugs
-
-
2.2 By Type of Disease
-
2.2.1 Acute Hyperkalemia
-
2.2.2 Chronic Hyperkalemia
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Hyperkalemia Treatment Market Size FAQs
What is the current Hyperkalemia Treatment Market size?
The Hyperkalemia Treatment Market is projected to register a CAGR of 16.79% during the forecast period (2024-2029)
Who are the key players in Hyperkalemia Treatment Market?
Sanofi S.A., Perrigo Company plc, CSL Limited (Vifor Pharma Management Ltd.), AstraZeneca and Ardelyx are the major companies operating in the Hyperkalemia Treatment Market.
